Accelerating and Optimizing Biopharmaceutical Process and Product Development

Who's Attending?

Network with 1,500+ bioprocess professionals from around the world. See who you will meet at BPI 2010

Keynote Presentations

Regulatory Modernization - FDA's Desired State for Product Quality
Helen N. Winkle, Director, Office of Pharmaceutical Science, CDER, US FDA

The Role of Biosimilars in Driving Innovation in the Biopharmaceutical Industry
Thomas J. Vanden Boom, Ph.D., Vice President, Global Biologics R&D, Hospira, Inc.

Sustainable Commercial Cell Culture Operations
W. Blair Okita, Ph.D., Senior Vice President, Manufacturing Sciences and Technical Operations, Genzyme Corporation

Finding a Home for Process and Product Development
S. Robert Adamson, Ph.D., Advance Biotech Consultants; former Senior Vice President Product and Process Development, Wyeth Biopharma

Exhibit Hall & Keynote Pass Now Available

• $25 When you regsiter by August 27
• $50 When you register by Setpember 15
• $100 after September 15

» Read more

Special Discounted Hotel Rate

Special Discounted Hotel Rate Available Until August 20, 2010.
To book your room, call 1-800-937-8461 and reference IBC Life Sciences - BPI 2010.
» More Information

Space is Limited... Reserve Your Booth Today!

Over 75% of the Exhibit Space is already SOLD!
Download the 2010 Sponsor/Exhibitor Overview Information & Floor Plan

Can't Attend in 2010?

Mark Your Calendar for BPI 2011!
October 31 - November 4, 2011
Long Beach Convention Center

This is the one conference you need to attend this year if your goals are to:

• Streamline your processes by adopting new technologies or improving current manufacturing operations
• Implement QbD
• Manufacture patient-friendly biopharmaceuticals in a cost-effective manner
• Expedite your candidates through the CMC approval process
• Manage process changes in your post-approval products

"A must-attend annual conference for biopharmaceutical industry!"
- Jinyou Zhang, Ph.D., Associate VP, Process Development & Manufacturing, Immunomedics, Inc.

Top Eleven Reasons Why BPI Should Be Your #1 Conference Choice this Year

1. Advance your knowledge quickly and comprehensively with BPI's broad coverage and detailed case studies.
2. Maximize your present and future facilities by hearing case studies and experiences with biodefense, subcutaneous high concentration dosing, high titre projects and many other cutting-edge case programs and strategies
3. Learn to use design space strategies to leverage flexibility, mitigate variability, and continuously improve your process
4. Plan how to integrate raw materials and suppliers into your quality system by applying science- and risk-based approaches to fulfill your responsibility to both shareholders and patients
5. Hear what comes next after titer increase as companies demonstrate approaches to accelerate process development and control costs while improving quality in upstream processing
6. Learn to optimize the interface and hand-offs between upstream and downstream processing
7. Hear behind-the-scenes thinking about today's bioprocessing realities and tomorrow's possibilities during small group break-out discussions - to ensure the direction of your career and your company's projects
8. Tour Amgen's State-of-the-Art BioNext Facility and gain first-hand knowledge of an industry leader's operations
9. Streamline your projects by developing alliances with providers you meet in the largest exhibit hall exclusively devoted to biopharmaceutical manufacturing
10. Connect with peers facing similar development and product challenges as you are, so that you can develop new collaborations and relationships to continue the dialogue after the event
11. Gain recognition from your peers as you showcase your accomplishments and share experiences by presenting a poster

"The premier annual bioprocessing event for the development of biologics. The BPI conference is one meeting that everyone looks forward to attending."
- Denny Kraichely, Ph.D., CMC Team Leader, Portfolio Management & Technical Integration, Janssen Pharmaceutical Companies of Johnson & Johnson